No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IONS240816C42500
- 6.33
- +1.00+18.76%
15min DelayClose Jul 22 09:30 ET
6.75High6.33Low
6.75Open5.33Pre Close2 Volume146 Open Interest42.50Strike Price1.31KTurnover51.89%IV-3.52%PremiumAug 16, 2024Expiry Date8.11Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9149Delta0.0225Gamma5.92Leverage Ratio-0.0265Theta0.0262Rho5.42Eff Leverage0.0208Vega
Intraday
- 5D
- Daily
News
Express News | Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
Ionis Pharmaceuticals Shares Rise After Positive Results for Angelman Syndrome Drug Study
Ionis Pharmaceuticals (IONS) said Monday that results from the multiple ascending dose part of phase 1/2 study of ION582 showed consistent clinical improvement of all functional domains in patients
Express News | Ionis Pharmaceuticals: 97% Of Patients in Medium and High Dose Groups Saw Improvement in Overall Angelman Syndrome Symptoms
Express News | Ionis Pharmaceuticals Inc - to Initiate Phase 3 Development in H1 2025
Express News | Ionis Announces Positive Detailed Results From the Halos Study of Ion582 in People With Angelman Syndrome
Comments
$Ionis Pharmaceuticals(IONS.US$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
1
Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.
2
Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.
Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.
Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.
Read more